HIV medications: Difference between revisions
From IDWiki
Content deleted Content added
| Line 131: | Line 131: | ||
== Single-Tablet Regimens == |
== Single-Tablet Regimens == |
||
{| class="wikitable" |
{| class="wikitable sortable" |
||
! Brand name |
! Brand name |
||
! NRTIs |
! NRTIs |
||
! Non-NRTI |
! Non-NRTI |
||
! First-line? |
|||
! Notes |
! Notes |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
|- |
|- |
||
| Atripla |
| Atripla |
||
| [[tenofovir disoproxil fumarate]] / [[emtricitabine]] |
| [[tenofovir disoproxil fumarate]] / [[emtricitabine]] |
||
| [[efavirenz]] |
| [[efavirenz]] (NNRTI) |
||
| No |
|||
| Older regimen. Neuropsychiatric symptoms, possibly including suicide. |
| Older regimen. Neuropsychiatric symptoms, possibly including suicide. |
||
| ⚫ | |||
| ⚫ | |||
| [[tenofovir alafenamide]] / [[emtricitabine]] |
|||
| [[bictegravir]] (INI) |
|||
| Yes |
|||
| |
|||
|- |
|- |
||
| Complera |
| Complera |
||
| [[tenofovir disoproxil fumarate]] / [[emtricitabine]] |
| [[tenofovir disoproxil fumarate]] / [[emtricitabine]] |
||
| [[rilpivirine]] |
| [[rilpivirine]] (NNRTI) |
||
| No |
|||
| Avoid with viral loads (>100,000) or low CD4 (<200). Pill must be taken with food (>400kcal) and without PPIs. |
| Avoid with viral loads (>100,000) or low CD4 (<200). Pill must be taken with food (>400kcal) and without PPIs. |
||
|- |
|- |
||
| Delstrigo |
|||
| ⚫ | |||
| [[tenofovir disoproxil fumarate]] / [[ |
| [[tenofovir disoproxil fumarate]] / [[lamivudine]] |
||
| [[ |
| [[doravirine]] (NNRTI) |
||
| No |
|||
| ⚫ | |||
| |
|||
|- |
|||
| Dovato |
|||
| [[emtricitabine]] |
|||
| ⚫ | |||
| Yes |
|||
| Two-medication regimen |
|||
|- |
|- |
||
| Genvoya |
| Genvoya |
||
| [[tenofovir alafenamide]] / [[emtricitabine]] |
| [[tenofovir alafenamide]] / [[emtricitabine]] |
||
| [[elvitegravir]]/[[cobicistat]] (INI) |
| [[elvitegravir]]/[[cobicistat]] (INI) |
||
| |
|||
| See Stribild, above. |
| See Stribild, above. |
||
|- |
|- |
||
| Odefsey |
|||
| ⚫ | |||
| [[tenofovir alafenamide]] / [[emtricitabine]] |
| [[tenofovir alafenamide]] / [[emtricitabine]] |
||
| [[ |
| [[rilpivirine]] (NNRTI) |
||
| No |
|||
| |
| |
||
|- |
|||
| ⚫ | |||
| [[tenofovir disoproxil fumarate]] / [[emtricitabine]] |
|||
| [[elvitegravir]]/[[cobicistat]] (INI) |
|||
| No |
|||
| ⚫ | |||
|- |
|||
| Symfi |
|||
| [[tenofovir disoproxil fumarate]] / [[emtricitabine]] |
|||
| [[efavirenz]] (NNRTI) |
|||
| No |
|||
| |
|||
|- |
|||
| Symtuza |
|||
| [[tenofovir alafenamide]] / [[emtricitabine]] |
|||
| [[darunavir]]/[[cobicistat]] (PI) |
|||
| No |
|||
| |
|||
|- |
|||
| ⚫ | |||
| ⚫ | |||
| [[dolutegravir]] (INI) |
|||
| Yes |
|||
| ⚫ | |||
|} |
|} |
||
Revision as of 14:46, 12 February 2020
Classes
| Class | Examples | Description |
|---|---|---|
| Nucleoside reverse-transcriptase inhibitor (NRTI) | tenofovir, emtricitabine, abacavir | Nucleoside/nucleotide analogues that get incorporated into viral DNA by reverse transcriptase, causing missense or non-sense mutations. The backbone of HIV treatments, with a high barrier to resistance. |
| Non-NRTI | efavirenz | Actively inhibit reverse transcriptase at its active site. Resistance develops with a single point mutation. |
| Protease inhibitor (PI) | dirunavir | Inhibits protease, which is required for processing proteins in the creation of the virion. Causes a metabolic syndrome. |
| Integrase strand transfer inhibitor (INSTI) | raltegravir, dolutegravir, bictegravir | Extremely potent with few side effects. Take separate from PPIs etc. |
| Fusion inhibitor | ||
| CCR5 inhibitor | ||
| CD4-mAb | ibalizumab | Blocks entry of HIV into CD4 cells. |
Specific Medications
| Medication | AKA | Class | Notes |
|---|---|---|---|
| lamivudine | 3TC | NRTI | |
| emtricitabine | FTC | NRTI | |
| tenofovir disoproxol fumarate | TDF | NRTI | |
| tenofovir alafenamide | TAF | NRTI | Fewer renal and bone effects. |
| zidovudine | AZT | NRTI | |
| abacavir | ABC | NRTI | Need to check HLA-B*5701 before starting therapy. |
| efavirenz | EFZ | NNRTI | |
| rilpivirine | RPV | NNRTI | Take with meal, not with PPI. |
| doravirine | DOR | NNRTI | |
| lopinavir/ritonavir | LPV/r | PI | GI side effects. |
| darunivir | DRV | PI | |
| dolutegravir | DTG | INSTI | Increases metformin levels. Avoid in pregnancy. |
| elvitegravir/cobicistat | EVG/c | INSTI | Requires booster that has drug interaction. |
| raltegravir | RAL | INSTI | First INSTI. BID dosing. Only INSTI that can be used in pregnancy. |
| bictegravir | BIC | INSTI | |
| cabotegravir | CAB | INSTI | Long-acting injectable available. |
| ibalizumab | CD4-receptor antibody. |
Single-Tablet Regimens
| Brand name | NRTIs | Non-NRTI | First-line? | Notes |
|---|---|---|---|---|
| Atripla | tenofovir disoproxil fumarate / emtricitabine | efavirenz (NNRTI) | No | Older regimen. Neuropsychiatric symptoms, possibly including suicide. |
| Biktarvy | tenofovir alafenamide / emtricitabine | bictegravir (INI) | Yes | |
| Complera | tenofovir disoproxil fumarate / emtricitabine | rilpivirine (NNRTI) | No | Avoid with viral loads (>100,000) or low CD4 (<200). Pill must be taken with food (>400kcal) and without PPIs. |
| Delstrigo | tenofovir disoproxil fumarate / lamivudine | doravirine (NNRTI) | No | |
| Dovato | emtricitabine | dolutegravir (INI) | Yes | Two-medication regimen |
| Genvoya | tenofovir alafenamide / emtricitabine | elvitegravir/cobicistat (INI) | See Stribild, above. | |
| Odefsey | tenofovir alafenamide / emtricitabine | rilpivirine (NNRTI) | No | |
| Stribild | tenofovir disoproxil fumarate / emtricitabine | elvitegravir/cobicistat (INI) | No | Includes a P450 inhibitor to boost elvitegravir levels, with resultant drug-drug interactions. Avoid if CrCl <70. |
| Symfi | tenofovir disoproxil fumarate / emtricitabine | efavirenz (NNRTI) | No | |
| Symtuza | tenofovir alafenamide / emtricitabine | darunavir/cobicistat (PI) | No | |
| Triumeq | abacavir / lamivudine | dolutegravir (INI) | Yes | Highest barrier to resistance. Need to test for HLA-B5701 allele before starting. Avoid in hepatitis B coinfection. |
Considerations
- Hepatitis B: Avoid Triumeq; use TDF/FTC-based regimen instead
- CKD: Avoid Stribild in CrCl <70
Further Reading
- Andany N and Gold WL. Five things to know about single-tablet antiretroviral treatment (once daily). CMAJ. 2016;188(13)971.
- Gandhi M and Gandhi RT. Single-Pill Combination Regimens for Treatment of HIV-1 Infection. N Engl J Med. 2014;371:248-259.